BiondVax Pharmaceuticals
2003
FOUNDED
PUBLIC
STATUS
21-30
EMPLOYEES
BVXV
STOCK SYMBOL
$6.00
SHARE PRICE
(As of Friday Closing)
Description
BiondVax Pharmaceuticals Ltd is engaged in the healthcare sector. Its main activity is the commercialization and manufacturing of flu vaccine. Its product is designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains. The company recently concluded two Phase I/II trials in which the multimeric-001 universal flu vaccine was shown to be safe and immunogenic.
Primary Industry
Other Healthcare Services
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- Weizmann Science Park
- PO Box 4143, 14 Einstein Street
- Ness Ziona 7403618
- Israel
+972 00-000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore BiondVax Pharmaceuticals’s full profile, request a free trial.
BiondVax Pharmaceuticals Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $3.51 - $7.26 | $39.2M | $5.77 | -$3.16 | 5.18K | 6.54M |
BiondVax Pharmaceuticals Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 6,972 | 8,953 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (19,560) | (21,359) | (9,489) | (2,245) |
| Net Income | (20,035) | (24,396) | (9,606) | (2,392) |
| Total Assets | 27,386 | 28,102 | 23,505 | 7,828 |
| Total Debt | 26,658 | 25,054 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
BiondVax Pharmaceuticals Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore BiondVax Pharmaceuticals‘s full profile, request access.
Request full access to PitchBookBiondVax Pharmaceuticals Competitors (1)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| 000 00000000(00000 | Corporate Backed or Acquired | Cambridge, MA | 000 | 000.00 | 00000000 | 000.00 |
BiondVax Pharmaceuticals Executive Team (4)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Ron Babecoff | Chief Executive Officer & Founder | ||
| Shimon Hassin Ph.D | Chief Operating Officer | ||
| Tamar Ben-Yedidia Ph.D | Chief Scientific Officer |
1 Former Executive
You’re viewing 3 of 4 executives. Get the full list »BiondVax Pharmaceuticals Board Members (4)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Avner Rotman Ph.D | BiondVax Pharmaceuticals | Chairman & Board Member | 000 0000 | |
| Mark Germain | Self | Vice Chairman | 000 0000 | |
| Morris Laster MD | Self | Board Member | 000 0000 | |
| Ruth Yakar Ph.D | Self | Board Member | 000 0000 |